---
title: "LifeMine's $188M Series E: Fungal Biology Meets Transplant Drugs"
description: "LifeMine raised an oversubscribed $188M Series E (plus a prior $75M Series D) to push LIFE-001 — a novel calcineurin-pathway immunosuppressant — toward Phase 2 kidney transplant studies, with ARCH among continuing backers."
date: 2026-08-06T00:00:00.000Z
tags: ["2026-vc-news", "startup-funding", "venture-capital", "biotech", "healthcare"]
source: https://venturecapitaltracker.com/2026-lifemine-188m-series-e-transplant-drug
---

# LifeMine's $188M Series E: Fungal Biology Meets Transplant Drugs

> LifeMine raised an oversubscribed $188M Series E (plus a prior $75M Series D) to push LIFE-001 — a novel calcineurin-pathway immunosuppressant — toward Phase 2 kidney transplant studies, with ARCH among continuing backers.

**LifeMine Therapeutics** announced **$263 million** in new capital on **August 6, 2026** — an oversubscribed **$188M Series E** led by **Milky Way Investments**, plus a previously unannounced **$75M Series D** (Q4 2025). New names include **Bezos Expeditions**, **Gates Frontier**, and **RA Capital**; continuing backers include **GV**, **GSK**, **Invus**, and [ARCH Venture Partners](/fund/arch-venture-partners).

## Key facts

| Field | Detail |
| --- | --- |
| Company | LifeMine Therapeutics (Watertown, MA) — genomically enabled fungal natural products |
| Asset | LIFE-001 — novel calcineurin-activation inhibitor for transplant rejection |
| Round | $188M Series E (+ $75M Series D) |
| Date | Announced August 6, 2026 |
| Lead (E) | Milky Way Investments (Rick Klausner) |
| New (E) | Bezos Expeditions, Gates Frontier, RA Capital |
| Continuing | GV, GSK, Invus, LoLa, ARCH Venture Partners |
| Next clinical | Phase 2 kidney + Phase 1b islet (early 2027 guidance) |
| Founder signal | Greg Verdine / Rick Klausner orbit; GSK research collab history |

## Who uses the product — and for what job

**End users (if approved):** transplant physicians and patients who need immunosuppression with a better safety/tolerability profile than legacy calcineurin inhibitors.

**Near-term “users”:** Phase 1/2 clinical sites; development and commercial ops building toward kidney and islet indications.

**Job:** prevent organ rejection with a **mechanistically novel** oral candidate — company claims Phase 1 signals support a potential best-in-class profile vs legacy CNIs (company-reported; not a regulatory conclusion).

## Why now

- Organ transplant still runs on decades-old immunosuppressant tradeoffs (efficacy vs toxicity).
- Late-stage biotech capital returned selectively in 2026 to **clear clinical stories**, not platform decks alone.
- Celebrity/sovereign-adjacent LPs (Bezos, Gates) often show up when a program has **human data + huge unmet need**.

Unexpected truth: the headline names are Bezos/Gates; the **diligence continuity** is ARCH/GV/GSK — platform investors who already lived through LifeMine’s science risk.

## Why ARCH (and this syndicate) — portfolio fit

**[ARCH Venture Partners](/fund/arch-venture-partners)** is a life-sciences specialist that originates and scales deep biology companies. LifeMine’s pitch — evolutionary fungal chemistry + modern discovery — matches ARCH’s “start from the science” model more than a generalist AI fund.

**Likely company rationale for this raise:**
- Series E size funds **Phase 2-scale clinical burn**.
- Milky Way (Klausner) as lead keeps scientific governance tight.
- Bezos/Gates/RA add capital + signal without replacing biotech-native boards.
- Keep ARCH/GV/GSK for continuity through modality risk.

**Portfolio fit (judgment):** ARCH’s biotech-life-sciences sector tag; this is clinical-stage capital, not a seed incubation check — participation, not a new company creation event.

## Competitive map

| Player | Lane |
| --- | --- |
| Legacy CNIs (tacrolimus, cyclosporine) | Standard of care; toxicity baggage |
| Other next-gen immunosuppressants | Alternative mechanisms in clinic/market |
| Cell/gene transplant adjuncts | Different modality; may combine |
| Big Pharma transplant franchises | Partners or competitors at commercialization |

## When not to model this as a quick win

- You need **approved revenue** this year — still clinical.
- You underwrite like SaaS ARR — burn is trial-driven.
- You ignore manufacturing/CMC risk for novel modalities.
- You treat Bezos/Gates participation as efficacy proof (it is capital signal, not Phase 3 data).

## Practical takeaway

- **Founders (bio):** Series E buyers want **Phase 1 clarity + Phase 2 plan**, not another platform rebrand.
- **Investors:** Separate platform value from single-asset risk; LIFE-001 is the near-term underwriting object.
- **Operators / clinicians:** Watch 2027 kidney Phase 2 design for differentiation vs CNI standard of care.

### Sources

1. Business Wire / FinancialContent (Aug 6, 2026): https://markets.financialcontent.com/stocks/article/bizwire-2026-8-6-lifemine-raises-263-million-to-accelerate-the-clinical-development-of-life-001-a-structurally-and-mechanistically-novel-calcineurin-activation-inhibitor-designed-to-transform-organ-transplantation
2. BioPharma Dive: https://www.biopharmadive.com/news/lifemine-organ-transplant-rejection-drug-greg-verdine-financing/827145/
3. Investor: [/fund/arch-venture-partners](/fund/arch-venture-partners)
4. Related: [/2026-biotech-healthtech-funding-may-june-2026](/2026-biotech-healthtech-funding-may-june-2026) · [/2026-august-6-7-investment-news-defense-autonomy-ai](/2026-august-6-7-investment-news-defense-autonomy-ai)